Sage Therapeutics(US:SAGE)2021-05-04 15:20Company Overview - Sage Therapeutics aims to be a top-tier biopharmaceutical company in the next 5 years[18] - The company has a rich pipeline across 3 franchises and goals of 2 or more IND-enabling programs per year by 2023[18] - Sage Therapeutics has over $2 billion in capital to fund efforts to impact an estimated >450 million patients globally[18] Depression Franchise (Zuranolone) - Approximately 70% of participants with positive response to an initial 2-week zuranolone treatment required at most one additional treatment during the 12-month SHORELINE study[34, 56] - In the SHORELINE study (30mg cohort), 42.9% of responders to initial treatment required only one course of zuranolone, while 25.6% needed 2 courses, 11.9% needed 3 courses, 10.8% needed 4 courses, and 8.8% needed 5 courses[56] - In the SHORELINE study, 23.9% exited the study with the primary reason of not achieving response in the first course of treatment[43] - In the 199 patients who received zuranolone 50 mg only, approximately 80.5% achieved response and 43.2% achieved remission after the initial 2-week treatment period[49, 52] Neurology Franchise (SAGE-324) - It's estimated that nearly 135 million people globally suffer from essential tremor (ET) or Parkinson's disease (PD)[67] - In an open-label, phase 1 study, a single dose of SAGE-324 resulted in nearly 50% tremor reduction in ET patients[69] - In the Phase 2 KINETIC Study, somnolence occurred in 68%, dizziness in 38%, balance disorder in 15%, diplopia in 12%, dysarthria in 12%, and gait disturbance in 12% of patients in the SAGE-324 treatment group[75] Neuropsychiatry Franchise (SAGE-718) - The 2020 economic burden of Alzheimer's disease in the US is estimated at ~$305 billion, compared to ~$200 billion in 2000[87]